Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSENS.L Regulatory News (SENS)

  • There is currently no data for SENS

Form 8 (OPD) - Replacement

16 Nov 2021 07:00

RNS Number : 5075S
Sensyne Health PLC
16 November 2021
 

THIS ANNOUNCEMENT REPLACES THE FORM 8 (OPD) ANNOUNCEMENT RELEASED UNDER RNS NUMBER 2902S ON 12 NOVEMBER 2021.

 

The following correction has been made to reflect the correct position as at 11 November 2021: the interests in ordinary shares of Sensyne Health plc held by Lord Paul Drayson and his close relatives, related trusts and connected persons. All other information remains unchanged.

 

CORRECTION: FORM 8 (OPD)

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

LORD PAUL DRAYSON

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

SENSYNE HEALTH PLC

(d) Is the discloser the offeror or the offeree?

OFFEROR

(e) Date position held:

The latest practicable date prior to the disclosure

11 NOVEMBER 2021

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

Ordinary shares of 10 pence each

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

40,594,574*

24.63*

Nil

-

(2) Cash-settled derivatives:

 

Nil

-

Nil

-

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

Nil

-

Nil

-

 

TOTAL:

40,594,574

24.63

Nil

-

 

*Figure and percentage include holdings of Lord Paul Drayson as well as those of his close relatives, related trusts and connected persons

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b) Rights to subscribe for new securities

 

Description of option / award

Number of ordinary Sensyne shares of 10 pence each under option / award

Date of grant

Exercise price

Vesting date

Lapse date

Sensyne Value Creation Plan (VCP)*

25,000 units

30 April 2021

175 pence or higher

22 July 2025

N/A

Sensyne Health Share Option Plan 2018

214,286 ordinary shares

17 August 2018

175 pence

17 August 2019

17 August 2028

 

\* The VCP is represented by a total of 100,000 plan units with participants permitted to share a pool of value created from the growth in value of Sensyne share capital after a five-year period ending on 23 July 2025.

 

 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

None

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

None

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

NO

Supplemental Form 8 (SBL)

NO

 

 

Date of disclosure:

12 November 2021

Contact name:

Lord Paul Drayson

Telephone number:

+44 330 058 1845

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DCCFIFEELRLRLIL
Date   Source Headline
3rd Nov 20213:00 pmBUSForm 8.3 - SENS LN
3rd Nov 20212:10 pmRNSForm 8.3 - Sensyne Health plc
3rd Nov 20211:54 pmRNSForm 8.3 - Sensyne Health Plc
3rd Nov 20211:10 pmRNSForm 8.3 - Sensyne Health Plc
3rd Nov 202112:58 pmGNWInvesco Ltd.: Form 8 (OPD) - Sensyne Health PLC
3rd Nov 202112:08 pmRNSHolding(s) in Company
3rd Nov 202112:00 pmRNSForm 8.5 (EPT/RI) - Sensyne Health Plc
3rd Nov 20219:51 amRNSForm 8.5 (EPT/RI)
3rd Nov 20218:23 amRNSForm 8.3 - Sensyne Health Plc
2nd Nov 20213:02 pmGNWForm 8.3 - Octopus Investments - Sensyne Health plc
2nd Nov 20217:00 amRNSStrategic update, FSP triggered by potential MBO
29th Oct 20215:04 pmRNSResults of Annual General Meeting
21st Oct 20217:00 amRNSMagnifEye European regulatory certification
15th Oct 20217:00 amRNSSensyne and OMNY Health Sign Teaming Agreement
6th Oct 20217:00 amRNSHoldings in Company
6th Oct 20217:00 amRNSAnnual Report and Accounts
4th Oct 20212:05 pmRNSSecond Price Monitoring Extn
4th Oct 20212:00 pmRNSPrice Monitoring Extension
1st Oct 20217:00 amRNSSensyne Health 2021 Financial Results
24th Sep 20217:00 amRNSNotice of Preliminary Results
9th Sep 20217:00 amRNSLaunch of SENSIGHT data analytics platform
2nd Sep 20217:00 amRNSSensyne & GOSH partner in child disease research
19th Aug 20217:00 amRNSSensyne SRA With Sentara Healthcare
10th Aug 20217:00 amRNSSensyne announces AI drug discovery project
2nd Aug 20217:01 amRNSBoard Change
2nd Aug 20217:00 amRNSSensyne dataset reaches 60m patients
22nd Jul 20217:00 amRNSAppointment of Chief Scientific Officer
19th Jul 20217:00 amRNSSensyne Health Provides Strategic Update
18th Jun 20217:00 amRNSNED Appointment
17th Jun 20213:02 pmRNSHolding(s) in Company
1st Jun 20217:00 amRNSMagnifEye Production Contract with UK DHSC
28th May 20212:24 pmRNSShare Option Award
27th May 20217:00 amRNSTrading Update
25th May 20211:13 pmRNSHolding(s) in Company
24th May 20217:00 amRNSSRA with Colorado Center for Personalized Medicine
21st May 20219:14 amRNSPharmaceutical collaboration
21st May 20217:00 amRNSSensyne signs SRA with St. Luke’s
7th May 202111:12 amRNSHolding(s) in Company
7th May 20217:00 amRNSMagnifEye Gains MHRA Approval
6th May 20217:00 amRNSValue Creation Plan Award
30th Apr 20217:00 amRNSSensyne SRA with Royal Devon and Exeter NHS Trust
16th Apr 20217:00 amRNSIssue of Shares and Total Voting Rights
12th Mar 20217:00 amRNSAgreement with the UK DHSC
1st Mar 20217:00 amRNSSYNE-COV Achieves UK Regulatory Approval
1st Mar 20217:00 amRNSBoard Changes
10th Feb 20212:06 pmRNSSecond Price Monitoring Extn
10th Feb 20212:00 pmRNSPrice Monitoring Extension
9th Feb 20217:48 amRNSSensyne licenses MagnifEye technology to Excalibur
5th Feb 20212:57 pmRNSHoldings in Company
5th Feb 20212:24 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.